Gewinn- und Verlustrechnung von Pfizer Inc.

They may not remain cheap for too much longer.

Healthcare has been an unloved corner of the market in 2026, but that neglect has created a rare setup: quality names trading in single-digit and low-double-digit territory while still throwing off cash, growing earnings, and reaffirming guidance.

Pfizer's estimated 2026 earnings easily cover its generous dividend. But Pfizer faces a patent cliff, and cash flow didn't cover the dividend last year.

AZN targets continued 2026 growth with expanding blockbuster medicines, a strong pipeline and 2030 revenue goals as it outpaces Pfizer on key metrics.

Healthcare has become Wall Street's bargain bin in 2026, and value hunters are starting to pay attention.

Pfizer (PFE) concluded the recent trading session at $23.72, signifying a -2.47% move from its prior day's close.

HSBC downgraded Pfizer Inc. (NYSE:PFE) on Monday, citing that the company's near-term re-rating prospects have weakened despite its attractive dividend yield and long-term oncology ambitions.

Rick Ducat points to Pfizer (PFE) as an underperformer in the healthcare sector and greater S&P 500 (SPX). However, shares of the company show some signs of strength that Rick believes sets the stage for a rebound even after the stock was hit with a recent downgrade.

One stands above the others.

Pre-Market Stock Futures: Futures are trading mixed as we get ready to start the first full week of trading for the third quarter, as traders and investors return from the long 4th of July holiday. With second-quarter earnings starting this week, and with all of the major indices trading at or near all-time highs, you... Here Are Monday's Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More